Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis

References

• Shichikawa K, Inoue K, Hirota S, Maeda A, Ota H, Kimura M, et al. Changes in the incidence and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965-1996. Ann Rheum Dis 1999;58(12):751–6.
   PubMed Web of Science ®Google Scholar
• Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 2002;4 Suppl 3:S265–72.
   PubMedGoogle Scholar
• Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Taniguchi, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3763 patients with rheumatoid arthritis. Arthritis Rheum 2003;49(6):784–8.
   PubMed Web of Science ®Google Scholar
• Mithal A, Yamanaka H, Tanaka EI, Nakajima A, Kamatani N. Medical costs for care of rheumatoid arthritis in Japan. In: ISPOR first Asia-Pacific conference; 2003 September 1–3; Kobe, Japan.
   Google Scholar
• American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46(2): 328–46.
   PubMedGoogle Scholar
• Yamanaka H, Mithal A, Tanaka EI, Nakajima A, Kamatani N. Medical costs are significantly associated with disability levels in rheumatoid arthritis in Japan. In: ISPOR first Asia-Pacific conference, September 1–3; Kobe, Japan; 2003.
   Google Scholar
• Schwartzman S, Fleischmann R, Morgan GJ, Jr. Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? Arthritis Res Ther 2004;6 Suppl 2:S3–11.
   Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343(22):1586–93.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46(6):1443–50.
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130(6):478–86.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340(4):253–9.
   PubMed Web of Science ®Google Scholar
• Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28(6):1238–44.
   PubMedGoogle Scholar
• Nishimura S, Torrance GW, Ikegami N, Fukuhara S, Drummond M, Schubert F. Information barriers to the implementation of economic evaluations in Japan. Pharmacoeconomics 2002;20 Suppl 2:9–15.
   PubMedGoogle Scholar
• Doherty J, Sato K. Practical aspects of designing and conducting pharmacoeconomic studies in Japan. Pharmacoeconomics 2003; 21(13):913–25.
   PubMedGoogle Scholar
• Matsuno H, Sugiyama E, Muraguchi A, Nezuka T, Kubo T, Matsuura K, et al. Pharmacological effects of SA96 (bucillamine) and its metabolites as immunomodulating drugs�the disulfide structure of SA-96 metabolites plays a critical role in the pharmacological action of the drug. Int J Immunopharmacol 1998;20(6): 295–304.
   PubMed Web of Science ®Google Scholar
• Azuma T. Epidemiology, prognosis and causes of death in rheumatoid arthritis. Nippon Rinsho 1992;50(3):637–43.
   Google Scholar
• Kawai S, Kato T, Matsuda T. Quality of life measures as clinical assessment of improvement in rheumatoid arthritis. Recent Adv Clin Pharmacol 2002;23:47–51.
   Google Scholar
• Ichikawa Y, Shinozawa T, Yoshida T, Kameda H, Suzuki Y, Kawai S, et al. [Methotrexate and salazosulfapyridine in the long-term treatment of rheumatoid arthritis]. Ryumachi (Rheumatism) 1995;35(4):663–70.
   PubMedGoogle Scholar
• Ota H, Tanno M, Tanaka H, Kobayashi M, Yoshino S. Correlation between the health assessment questionnaire (HAQ) and utility value in rheumatoid arthritis patients. In: ISPOR first Asia-Pacific conference, September 1–3; Kobe, Japan; 2003.
   Google Scholar
• Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford) 2004;43(1):62–72.
   PubMedGoogle Scholar
• Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159(21): 2542–50.
   Google Scholar
• Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353(9149):259–66.
   PubMed Web of Science ®Google Scholar
• Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004;39(3):295–9.
   PubMed Web of Science ®Google Scholar
• Kashiwazaki S, Ichikawa Y, Sugawara S, Nagaya I, Kawai S, Hakota M, et al. Determination of the clinical optimal dose of L-377 (methotrexate capsule) for the treatment of rheumatoid arthritis. Jpn J Inflamm 1996;16(6):437–57.
   Google Scholar
• Nishioka N, Nobunaga M, Sakuma A. [A double blind comparative study of 1 g/day, 2 g/day salazosulfapyridine and placebo in rheumatoid arthritis]. Ryumachi (Rheumatism) 1991;31(3):327–45.
   Google Scholar
• Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004;43(2):143–7.
   PubMed Web of Science ®Google Scholar
• Wages and Labour Welfare Statistics Division, Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare. Report of Basic Survey on Wage Structure, 2001. Japan: 2002.
   Google Scholar
• Population Census Division, Statistical Survey Department, Statistics Bureau, Ministry of Public Management, Home Affairs, Post and Telecommunications. Annual Report on the Labour Force Survey. Tokyo: Japan Statistical Association; 2002.
   Google Scholar
• Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare. Abridged Life Tables for Japan 2003. On Ministry website (updated 2004 Aug 18; cited 2004 Nov 23). Available from: http://www.mhlw.go.jp/english/database/ db-hw/lifetb03/.
   Google Scholar
• Wolfe F, Kleinheksel SM, Cathey MA, Hawley DJ, Spitz PW, Fries JF. The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis. J Rheumatol 1988;15(10):1480–8.
   PubMedGoogle Scholar
• National Institute for Clinical Excellence. Guidance for Manufacturers and Sponsors. London, England: National Institute for Clinical Excellence; 2001.
   Google Scholar
• Merkesdal S, Ruof J, Mittendorf T, Zeidler H. Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis. Expert Opin Pharmacother 2004;5(9):1881–6.
   PubMed Web of Science ®Google Scholar
• Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998;13(10):716–7.
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Guide to the methods of technology appraisal. On National Institute for Clinical Excellence website (updated 2004 Apr 30; cited 2004 May 5). Available from: http://www.nice.org.uk/pdf/TAP_Methods.pdf.
   Google Scholar
• Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004;63(1):4–10.
   Google Scholar
• Ota H, Tanno M, Tanaka H, Kobayashi M, Yoshino S. Patient reported outcomes for rheumatoid arthritis in Japan. In: ISPOR first Asia-Pacific conference, September 1–3; Kobe, Japan; 2003.
   Google Scholar
• Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum 2003;48(6):1493–9.
   PubMedGoogle Scholar
• Klareskog L, van der Heijde D, De Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363(9410):675–81.
   PubMed Web of Science ®Google Scholar